Drugs / Mivebresib
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04480086 | Mar 2021 → Jul 2023 | myelofibrosis | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02391480 | Apr 2015 → Jul 2019 | acute myeloid leukemia, breast cancer, non-Hodgkin lymphoma, non-small cell lung carcinoma +3 | AbbVie | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mivebresib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04480086 ↗ |
| Known as | ABBV-075 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02391480 ↗ |
| Action | Inhibit | “pan-BET inhibitor mivebresib (ABBV-075)” PMID 31420359 ↗ Aug 2019 |
| Modality | Small molecule | — CHEMBL3987016 ↗ |
| Route | Oral | “ABBV-075 Oral tablets” NCT02391480 ↗ |